Antiplatelet monotherapy after DAPT: is clopidogrel the new standard? Pros and cons.

, , ,

제1저자 강지훈 · 교신저자 김효수, De Caterina R.

소속 (5)

Department of Internal Medicine and Cardiovascular Centre, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.
University of Pisa and Cardiovascular Division 1, Pisa University Hospital, Pisa, Italy.
Fondazione VillaSerena per la Ricerca, Città Sant'Angelo, Pescara, Italy.

Conflict of interest statement

The authors have no conflicts of interest to declare. The authors have no conflicts of interest to declare.

그 밖의 정보

출판 형태: Editorial
저널: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · eISSN 1969-6213
전자 출판: 2024-06-17
MeSH: Humans · Platelet Aggregation Inhibitors* / therapeutic use / adverse effects · Clopidogrel* / therapeutic use / adverse effects · Percutaneous Coronary Intervention / adverse effects · Treatment Outcome
Substances: Platelet Aggregation Inhibitors · Clopidogrel
참고문헌: 10편